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ABSTRACT
The development of Imatinib mesylate (IM), which targets the oncogenic BCR-
ABL fusion protein, has greatly improved the outcome of Chronic Myeloid Leukemia 
(CML) patients. However, BCR-ABL–positive progenitors can be detected in CML 
patients in complete cytogenetic response. Several evidence suggests that CML stem 
cells are intrinsically resistant to Tyrosine Kinase Inhibitors (TKI), and therefore they 
represent the most likely candidate responsible for disease relapse.
In this work, we investigated the microRNA (miRNA) expression profile of different 
subpopulations of CML Leukemic Stem Cells (LSCs): Lin-CD34+CD38- and Lin-CD34-
CD38- cells. These cell fractions have been previously shown to be endowed with TKI 
intrinsic resistance. Our analysis identified 33 common deregulated miRNAs in CML 
LSCs. Among those, 8 miRNAs were deregulated in CML independently from BCR-ABL 
kinase activity and therefore are likely to be involved in the BCR-ABL-independent 
resistance to TKI that characterizes CML LSCs. In particular, the up-regulation of 
miR-29a-3p and miR-660-5p observed in CML LSCs, led to the down-regulation of 
their respective targets TET2 and EPAS1 and conferred TKI-resistance to CML LSCs  
in vitro. On the other hand, miR-494-3p down-regulation in CML LSCs, leading to c-MYC  
up-regulation, was able to decrease TKI-induced apoptosis. These results demonstrate 
that aberrant miRNA expression in CML LSCs could contribute to the intrinsic TKI-
resistance observed in these cell populations, and support the development of novel 
therapies aimed at targeting aberrantly regulated miRNAs or their targets in order to 
effectively eradicate CML LSCs.
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INTRODUCTION
Chronic Myeloid Leukemia (CML) is a stem cell-
derived malignant disorder characterized by the reciprocal 
translocation t(9;22) leading to the BCR-ABL fusion gene. 
The encoded 210 KDa protein has constitutively elevated 
tyrosine kinase activity and drives Hematopoietic Stem 
Cells (HSCs) transformation [1]. The BCR-ABL Tyrosine 
Kinase Inhibitors (TKIs), such as Imatinib mesylate, 
are the standard therapy for CML patients. Imatinib has 
been shown to induce complete molecular response in 
more than 80% of newly diagnosed patients in chronic 
phase [2]. However, it has been unable to completely 
eliminate BCR-ABL-expressing leukemic cells [3]. In 
order to achieve durable remission, CML patients require 
lifelong treatment with TKIs, at considerable cost and 
despite harmful side effects. There is an increasing body of 
evidence suggesting that TKIs are not effective in killing 
leukemic stem cells (LSCs) in CML [4, 5]. In particular, 
Corbin et al. demonstrated that CML LSCs survive IM 
treatment independently of BCR-ABL kinase activity [4]. 
Recently, our group identified a novel quiescent LSCs 
subset (Lin-CD34-CD38-), endowed with stem cell 
properties and intrinsically resistant to TKI treatment both 
in vitro and in vivo [6]. It is therefore clear that a definitive 
treatment for CML requires the elimination of LSCs. 
Thus, gaining further understanding on the molecular 
and functional properties of the stem cell compartment in 
CML is mandatory for the development of more effective 
therapies that will eliminate TKI-resistant LSCs.
MicroRNAs (miRNAs) are small non-coding RNAs 
that control gene expression and play an important role 
in several biological processes such as differentiation [7], 
proliferation [8], and apoptosis [9]. In the last few years, 
increasing evidence shows that miRNAs expression is 
deregulated in both solid and hematological malignancies 
[10, 11] and that deregulated miRNAs can induce and/or 
maintain a leukemogenic state. 
In this study, we performed miRNA expression 
profiling (miEP) of Lin-CD34+CD38− and Lin-CD34-
CD38- cells isolated from 5 CML patients and 4 healthy 
donors. This analysis identified a set of miRNAs aberrantly 
expressed in CML LSCs. In order to identify those miRNAs 
involved in the LSC-specific TKI escape, miRNAs whose 
expression is deregulated in CML independently from BCR-
ABL kinase activity were selected. Our analysis allowed us 
to identify three novel miRNA/mRNA networks that confer 
BCR-ABL-independent TKI resistance to CML LSCs.
RESULTS
miRNA expression profiling of CML Lin-CD34-
CD38- and Lin-CD34+CD38− cells
In order to shed light on the molecular properties of 
the CML stem cell compartment, we performed miEP on 
Lin-CD34-CD38- and Lin-CD34+CD38− cells from 5 CML 
patients and 4 healthy donors. To explore the relationships 
between samples, we performed a Principal Component 
Analysis (PCA). Figure 1A shows that the CML samples 
clustered together and were clearly separated from control 
samples. Of note, PCA revealed that CML Lin-CD34-CD38- 
are closer to leukemic CD34+CD38+ and normal CD34+ 
subfractions whereas their normal counterparts cluster 
separately, in agreement with our previous findings on the 
gene expression profile [6]. Next, differentially expressed 
miRNAs (DEMs) in the comparison CML vs normal donors 
for each cell population were identified by two-tail unpaired 
t-Student test as described in Materials and Methods 
(Supplementary Table 2 and Supplementary Table 3). This 
analysis identified 134 DEMs in the comparison CML Lin-
CD34-CD38-vs Normal Donor Lin-CD34-CD38− and 
102 DEMs in the comparison CML Lin-CD34+CD38−
vs Normal Donor Lin-CD34+CD38−. 33 miRNAs 
resulted concordantly deregulated in both cell populations 
(Figure 1B, Table 1, Supplementary Tables 5 and 6).
Identification of BCR-ABL-independent 
deregulated miRNAs
miRNAs can be deregulated in CML through either 
a BCR-ABL kinase-dependent or a kinase-independent 
mechanism. To identify those miRNAs that were aberrantly 
expressed in CML LSCs through a BCR-ABL-independent 
mechanism, we selected miRNAs whose expression did 
not change after IM treatment. To this end, the BCR-
ABL-positive K562 cells were treated with increasing 
doses of IM and the expression level of selected miRNAs 
was measured. For this analysis, 11 miRNAs, among the 
common 33 DEMs identified above, were selected based 
on their Fold Change (FC) in the comparison LSCs vs 
HSCs,  and on their biological significance, evaluated 
as biological function, and expression level in other 
Myeloproliferative Neoplasms from our database [12]. The 
effectiveness of IM treatment on BCR-ABL kinase activity 
was assessed by measuring CrkL phosphorylation (p-CrkL) 
by flow cytometry. As shown in Figure 1C, the intracellular 
p-CrkL levels were significantly decreased in IM-treated 
samples compared to the untreated control. 8 miRNAs 
(miR-660-5p, miR-365-3p, miR-29a-3p, miR-19b2-3p, 
miR-494-3p, miR-204-5p, miR-486-5p and miR-486-3p) 
showed no statistically significant difference in their 
expression level after IM treatment (Figure 1D, 1E). These 
miRNAs were therefore classified as deregulated in CML 
with a BCR-ABL independent mechanism (Figure 1F). 
miR-29a-3p protects CML cells from TKIs-
induced apoptosis
In order to assess whether miR-29a-3p up-regulation 
observed in CML LSCs is involved in the escape from 
TKIs treatment, miR-29a-3p was overexpressed in K562 
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cells and its effects on BCR-ABL kinase activity and 
cell survival in presence of TKIs treatment (1 µM IM 
for 24 h or 0.4 µM IM for 48 h, or 10 nM Ponatinib for 
24 h, or 100 nM Dasatinib for 24 h) were evaluated. A 
significant overexpression of miR-29a-3p was detected by 
qRT-PCR 24 hours after last nucleofection (RQ ± SEM, 
42.75 ± 6.04, p < 0.01) (Figure 2A). Analysis of p-CRKL 
levels showed that IM treatment significantly inhibited 
BCR-ABL kinase activity in all samples tested, regardless 
of miR-29a-3p overexpression (Figure 2B). Thus, miR-
29a-3p does not directly affect BCR-ABL activity.
Interestingly, flow cytometric analysis of apoptosis 
performed by PI/Annexin V staining showed a significant 
decrease in the percentage of apoptotic cells in the sample 
transfected with miR-29a-3p mimic compared to the Neg 
CTR mimic, when incubated with IM (Figure 2C–2E) as 
well as with second and third generation TKIs (Figure 2F, 
Supplementary Figure 3). 
Altogether, these data suggest that miR-29a-3p 
overexpression is able to protect K562 cells from TKIs-
induced apoptosis without affecting BCR-ABL kinase 
activity.
miR-29a-3p exerts its effects through TET2 
targeting
In order to unravel the molecular mechanisms 
underlying the effects of miR-29a-3p on K562 cells, we 
investigated the mRNA expression level of miR-29a-3p 
putative targets identified through the TargetScan database 
(Figure 3B) (http://targetscan.org release 7.0). qRT-
PCR was performed upon miR-29a-3p overexpression 
and the relative quantity of putative miR-29a-3p targets 
(i.e. JARID2, TET2 and DNMT3A) was calculated. As 
shown in Figure 3A, only TET2 (tet methylcytosine 
dioxygenase 2) mRNA was downregulated upon miR-29a-
3p overexpression (RQ ± SEM, 0.49 ± 0.08, p < 0.01). To 
validate the direct interaction between miR-29a-3p and 
TET2, 3′UTR luciferase reporter assay was performed. The 
overexpression of miR-29a-3p did not affect the luciferase 
activity for the sample transfected with no 3′UTR, whilst 
it induced a statistically significant reduction in luciferase 
activity in the sample transfected with TET2 3′UTR reporter 
construct (Figure 3C), thus demonstrating for the first time 
that miR-29a-3p targets TET2 3′UTR. Furthermore, western 
blot (WB) analysis confirmed TET2 protein downregulation 
after miR-29a-3p overexpression (Figure 3D). 
Next, we investigated whether TET2 downregulation 
was able to reproduce the effects on IM sensitivity 
observed upon miR-29a-3p overexpression. To this end, 
TET2 expression was silenced in K562 cells by means 
of TET2 siRNAs. qRT-PCR analysis confirmed the 
downregulation of TET2 mRNA in TET2 siRNA sample 
compared to the control (RQ ± SEM, 0.507 ± 0.07, 
p < 0.01) (Figure 3E). Twenty-four hours after last 
nucleofection, K562 cells were treated with either 
1 µM IM for 24 h or 0.4 µM IM for 48 h, and p-CRKL 
intracellular levels and apoptosis were evaluated. In 
agreement with the results obtained upon miR-29a-3p 
overexpression, TET2 silencing did not affect IM 
inhibition on BCR-ABL kinase activity (Supplementary 
Figure 2A). Moreover, our data showed a statistically 
significant decrease in the percentage of apoptotic cells 
in TET2 siRNA sample compared to the NTsiRNA 
(Figure 3F–3H). Altogether, these results demonstrate that 
TET2 silencing is able to protect cells from IM-induced 
apoptosis, thus phenocopying the effects mediated by 
miR-29a-3p overexpression.
miR-660-5p protects CML cells from TKIs-
induced apoptosis
Among miRNAs up-regulated in CML LSCs with a 
BCR-ABL-independent mechanism, our analysis pointed 
out miR-660-5p. In order to test whether its up-regulation 
is able to affect TKI sensitivity, K562 cells were transfected 
with either miR-660-5p mimic or Neg CTR mimic and 
BCR-ABL kinase activity and cell survival were evaluated 
by flow cytometric analysis. A significant overexpression 
of miR-660-5p was detected by qRT-PCR (RQ ± SEM, 
115.29 ± 6.28, p < 0.01) (Figure 4A). Flow cytometric 
analysis of p-CRKL intracellular level showed no 
statistically significant difference between cells transfected 
with Neg CTR mimic and miR-660-5p mimic (Figure 4B). 
Moreover, our data showed a statistically significant 
decrease in the percentage of apoptotic cells in the miR-660-
5p mimic sample compared to the Neg CTR mimic  after 
TKIs treatment (Figure 4C–4F, Supplementary Figure 3). 
These data demonstrate that miR-660-5p overexpression 
is able to protect K562 cells from TKIs induced apoptosis 
without affecting BCR-ABL kinase activity.
Then, in order to shed light on the molecular 
mechanisms responsible for miR-660-5p effects, we 
searched on the TargetScan database for putative miR-
660-5p targets. Between all predicted targets tested, only 
EPAS1 (endothelial PAS domain protein 1) transcript 
showed a statistically significant downregulation upon 
miR-660-5p overexpression (RQ ± SEM, 0.45 ± 0.07, 
p < 0.01) (Figure 5A). As shown in Figure 5B, EPAS1 
3′ untraslated region (3′UTR) displays two putative 
miRNA recognition elements (MRE), as reported by the 
target prediction tools TargetScanHuman and microRNA.
org (www.microrna.org). To validate the direct interaction 
between miR-660-5p and EPAS1, 3′UTR luciferase reporter 
assay was performed: results showed a statistically significant 
reduction in normalized luciferase activity in K562 cells 
co-nucleofected with miR-660-5p miRNA mimic and 
EPAS1 reporter construct (Figure 5C), thus demonstrating 
for the first time that miR-660-5p targets EPAS1 3′UTR. 
Furthermore, western blot (WB) analysis confirmed EPAS1 
protein downregulation after miR-660-5p overexpression 
(Figure 5D).
Next, EPAS1 expression was silenced in K562 cells by 
means of transfection with EPAS1 siRNA (EPAS1 siRNA). 
Oncotarget49454www.impactjournals.com/oncotarget
Figure 1: microRNAs expression data analysis. (A) The Principal Component Analysis (PCA)  graph of global miRNA expression 
data was computed using GenEx software version 6; CML Lin-CD34-CD38- are shown as blue cubes; CML Lin-CD34+CD38− are shown 
as green cubes, Normal Donor Lin-CD34-CD38- are shown as yellow cubes; CML Lin-CD34+CD38− are shown as red cubes. (B) Venn 
diagram showing the intersection of the lists of differentially expressed miRNAs (DEMs) in the comparison CML Lin-CD34-CD38- vs 
Normal Donor Lin-CD34-CD38- and CML Lin-CD34+CD38- vs Normal Donor Lin-CD34+CD38-. (C) Normalized MIF of intracellular 
p-CrkL levels in K562 cells after IM treatment. Untreated control pCRKL MIF was set to 1 to compare K562 before and after treatment 
with IM. The results are expressed as mean values ±SEM (n = 3), *p < 0.05, **p < 0.01 in untreated versus IM-treated cells. p-value from 
one-way ANOVA is 0.00002 (D) Real-Time PCR results showing expression levels of CML up-regulated miRNAs in K562 cells after IM 
treatment. (E) Real-Time PCR results showing expression levels of CML down-regulated miRNAs in K562 cells after IM treatment. Data 
are presented as Fold Change (FC) ± SEM (n = 3). FC of the untreated control was set to 1 to compare K562 before and after treatment with 
IM. BCR-ABL- independent miRNAs were identified as miRNAs with FC < 1.5 and > 0.67. (F) Relative expression level expressed as 
Fold Change (FC) of selected BCR-ABL-independent miRNAs in the comparisons CML Lin-CD34-CD38- vs Normal Donor Lin-CD34-
CD38- (black bars) and CML Lin-CD34+CD38- vs Normal Donor Lin-CD34+CD38- (striped bars). Abbreviations: MIF indicates Mean 
Fluorescence Intensity; IM, Imatinib Mesylate; NT, Not Treated.
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qRT-PCR analysis confirmed the downregulation of EPAS1 
mRNA in EPAS1 siRNA sample compared to the NTsiRNA 
(RQ ± SEM, 0.337 ± 0.05, p < 0.01) (Figure 5E). Twenty-
four hours after last transfection, K562 cells were treated 
with either 1uM IM for 24 h or 0.4 uM IM for 48h and cells 
were analyzed for apoptosis and pCRKL levels. Our results 
showed that EPAS1 silencing does not affect IM inhibitory 
effect on BCR-ABL kinase activity (Supplementary Figure 
2B). On the other hand, EPAS1 silencing was able to protect 
K562 cells from IM-induced apoptosis (Figure 5F–5H). 
Thus, these data demonstrate that EPAS1 silencing is able to 
reproduce the effects exerted by miR-660-5p overexpression, 
suggesting that miR-660-5p is able to protect cells from IM-
induced apoptosis through EPAS1 targeting.
miR-494-3p sensitizes CML cells to TKIs-
induced apoptosis
Among miRNAs down-regulated in CML LSCs 
with a BCR-ABL-independent mechanism, our analysis 
highlighted miR-494-3p. To assess whether the down-
regulation of miR-494-3p observed in CML LSCs can 
control response to first, second and third generation 
of TKIs, we overexpressed miR-494-3p in K562 cells 
and evaluated apoptosis and p-CRKL levels after TKIs 
treatment. qRT-PCR showed a significant up-regulation 
of miR-494-3p after miR-494-3p mimic transfection (RQ 
± SEM, 372.89 ± 86.92, p < 0.01) (Figure 6A). Flow 
cytometric analysis of p-CRKL intracellular level showed no 
statistically significant difference between cells transfected 
with Neg CTR mimic and miR-494-3p mimic (Figure 6B). 
These data suggest that miR-494-3p does not directly affect 
BCR-ABL kinase activity. Moreover, our data showed a 
statistically significant increase in the percentage of both 
apoptotic cells and late apoptotic/necrotic cells in miR-494-
3p mimic sample compared to the Neg CTR mimic (Figure 
6C–6F, Supplementary Figure 3). These results demonstrate 
that miR-494-3p overexpression is able to sensitize K562 
cells to TKIs-induced apoptosis without affecting BCR-ABL 
kinase activity.
miR-494-3p exerts its effects through c-MYC 
targeting
In order to identify the molecular mechanism 
responsible for the effects of miR-494-3p on K562 
cells sensitivity to TKIs, we performed a computational 
analysis for predicted miR-494-3p targets on TargetScan 
database (Figure 7B). Among all predicted targets 
tested (i.e. CDK6, HOXA10, PTEN and c-MYC), only 
c-MYC (v-myc avian myelocytomatosis viral oncogene 
homolog) transcript showed a statistically significant 
downregulation after miR-494-3p overexpression (RQ 
± SEM, 0.68 ± 0.08, p < 0.01) (Figure 7A). To validate 
the direct interaction between miR-494-3p and c-MYC we 
performed 3′UTR luciferase reporter assay. Our results 
showed a statistically significant reduction in luciferase 
activity in K562 cells co-nucleofected with miR-494-3p 
miRNA mimic and c-MYC reporter construct compared to 
the sample transfected with the 3′UTR-less vector (Figure 
7C), thus demonstrating a direct interaction between miR-
494-3p and c-MYC 3′UTR. Moreover, western blot (WB) 
analysis confirmed c-MYC protein downregulation after 
miR-494-3p overexpression (Figure 7D).
Next, c-MYC expression was silenced in K562 cells 
by means of siRNAs targeting c-MYC (MYC siRNA). 
qRT-PCR analysis confirmed c-MYC downregulation in 
MYC siRNA sample compared to the control (RQ ± SEM, 
0.38 ± 0.01, p < 0.01) (Figure 7E). In agreement with the 
results obtained upon miR-494-3p overexpression, c-MYC 
silencing did not affect IM inhibitory ability on BCR-ABL 
kinase activity (Supplementary Figure 2C). Moreover, 
our data showed a statistically significant increase in 
the percentage of both apoptotic and late apoptotic/
necrotic cells in the MYC siRNA sample compared to the 
NTsiRNA (Figure 7F–7H).
miR-29a-3p, miR-494-3p and miR-660-5p affect 
TKI sensitivity of CML LSCs
In order to assess whether the deregulated 
expression of miR-29a-3p, miR-494-3p and miR-660-5p 
is able to impact on CML LSCs’ sensitivity to TKIs, 
we overexpressed these miRNAs in Lin- cells isolated 
from 5 CML patients and evaluated apoptosis after TKIs 
treatment (10 µM IM for 24 h or 5 µM IM for 48 h, or 
20 nM Ponatinib for 48 h, or 200 nM Dasatinib for 48 h). 
A significant overexpression of miR-29a-3p, miR-494-3p 
and miR-660-5p was detected by qRT-PCR (RQ ± SEM, 
20.6 ± 1.8, 181.4 ± 16.1, 443.8 ± 37.5, respectively 
p < 0.05) (Figure 8A). Interestingly, flow cytometric 
analysis of apoptosis performed by PI/Annexin V 
staining showed a significant decrease in the percentage 
of cells in late apoptosis/necrosis in the samples 
transfected with either miR-29a-3p mimic or miR-660-5p 
mimic compared to the Neg CTR mimic (Figure 8B, 8C). 
Moreover, our data showed a strong increase in the 
percentage of late apoptotic/necrotic cells in the sample 
overexpressing miR-494-3p compared to the control 
(Figure 8B, 8C, Supplementary Tables 8 and 9). These 
differences were detected on the whole hematopoietic 
progenitor cells population (data not shown), as well as 
on the more primitive cell fractions, Lin-CD34-CD38- 
and Lin-CD34+CD38− (Figure 8B, 8C). 
DISCUSSION
Treatment of CML has been notably improved 
in the past 15 years thanks to the development of TKIs 
blocking BCR-ABL kinase activity. However, the majority 
of patients achieving remission with imatinib continue 
to test positive for BCR-ABL transcript by RT-PCR. 
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Indeed, in recent years, several in vitro evidence suggested 
that CML LSCs are intrinsically resistant to Imatinib. 
Chu et al. [5] demonstrated that BCR-ABL+ stem cells 
persist in the bone marrow of CML patients in prolonged 
remission on Imatinib treatment. Corbin et al. [4] 
demonstrated that CML LSCs survive Imatinib with a 
mechanism independent from BCR-ABL kinase activity. 
Notably, in vivo, only approximately 50% of patients who 
had stopped Imatinib therapy remained long-term disease 
free, at the molecular level, suggesting, in many cases, the 
persistence of LSCs [13]. Thus, treatment targeting BCR-
ABL does not completely eliminate CML stem cells, and 
disease eradication will require additional therapeutic 
strategies. In contrast, Mustjoki et al. recently reported 
Table 1: Common deregulated miRNAs in the comparison CML LSCs vs normal HSCs
miRNA ID
FC CML Lin-CD34-














hsa-miR-193b-3p 65,71 0,0007 61,54 0,0027
hsa-miR-501-3p 34,23 0,0083 3,61 0,0199
hsa-miR-1207-5p 31,88 0,0001 8,58 0,0091
hsa-miR-188-5p 26,71 0,0078 14,38 0,0054
hsa-miR-708-5p 26,53 0,0128 74,18 0,0017
hsa-miR-362-3p 22,61 0,0009 11,59 0,0006
hsa-miR-365a-3p 19,35 0,0258 3,61 0,0306
hsa-miR-532-3p 17,63 0,0001 4,40 0,0073
hsa-miR-660-5p 16,08 0,0002 12,19 0,0005
hsa-miR-502-3p 13,13 0,0011 4,54 0,0056
hsa-miR-532-5p 12,63 0,0008 4,56 0,0028
hsa-miR-150-5p 12,22 0,0274 5,58 0,0033
hsa-miR-500a-5p 11,46 0,0052 4,76 0,0271
hsa-miR-362-5p 8,90 0,0011 4,80 0,0047
hsa-miR-29a-3p 6,12 0,0001 2,59 0,0044
hsa-miR-22-3p 3,54 0,0320 7,52 0,0003
hsa-miR-142-3p 3,53 0,0272 5,15 0,0037
hsa-miR-21-5p 3,08 0,0477 9,70 0,0007
hsa-miR-125b-5p 2,53 0,0315 −3,49 0,0428
hsa-miR-155-5p 2,36 0,0244 −4,19 0,0077
hsa-miR-140-5p 2,17 0,0347 3,10 0,0060
hsa-miR-875-3p −2,35 0,0241 −4,62 0,0284
hsa-miR-494 −2,63 0,0197 −6,47 0,0509
hsa-miR-593-5p −2,67 0,0178 −4,91 0,0106
hsa-miR-518d-3p −2,72 0,0236 −7,90 0,0251
hsa-miR-609 −2,80 0,0270 −10,28 0,0303
hsa-miR-605 −3,86 0,0085 −10,94 0,0082
hsa-miR-134 −4,40 0,0009 −3,15 0,0375
hsa-miR-490-5p −6,20 0,0377 −13,82 0,0044
hsa-miR-33b-3p −7,33 0,0304 −7,71 0,0254
hsa-miR-625-3p −14,05 0,0245 −3,05 0,0110
hsa-miR-486-3p −14,21 0,0025 −26,46 0,0002
hsa-miR-204-5p −19,09 0,0007 −6,84 0,0245
hsa-miR-486-5p −25,31 0,0000 −15,86 0,0061
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Figure 2: Effects of miR-29a-3p overexpression on K562 cells’ response to TKIs. (A) Expression levels of miR-29a-3p 24 
hours after the last nucleofection as evaluated by qRT-PCR. Data are reported as RQ mean ± S.E.M of 3 independent experiments. (B) 
Normalized MIF of intracellular p-CrkL levels in K562 cells after miR-29a-3p overexpression. pCRKL MIF of the Neg CTR mimic 
untreated control was set to 1 to compare K562 before and after treatment with IM. The results are expressed as mean values ± SEM (n = 3). 
Results of Annexin V/PI staining on K562 cells after 24 h (C) and 48 h (D) of IM treatment (mean ± SEM; n = 3) *p < 0.05, **p < 0.01. 
Apoptotic cells (black bars in the histogram plot) are Annexin V bright and PI low, late apoptotic cells or necrotic cells (white bars in 
the histogram plot) are Annexin V and PI bright, grey bars represent cells bright for PI only. Representative dot plots for flow cytometry 
detection of Annexin V and PI staining at 24 h and 48 h after treatment are shown (E) i: Neg CTR mimic NT, ii: Neg CTR mimic IM 1 μM, 
iii: miR-29a-3p mimic NT, iv: miR-29a-3p mimic IM 1 μM, v: Neg CTR mimic NT, vi: Neg CTR mimic IM 0.4 μM, vii: miR-29a-3p mimic 
NT, viii: miR-29a-3p mimic IM 0.4 μM). (F) Results of Annexin V/PI staining on K562 cells after 24 h of 10 nM Ponatinib or 100 nM 
Dasatinib treatment (mean ± SEM; n = 3) *p < 0.05, **p < 0.01. Abbreviations: RQ, Relative Quantity; MIF indicates Mean Fluorescence 
Intensity; IM, Imatinib Mesylate; NT, Not Treated; 24 h, 24 hours; 48 h, 48 hours; PI, Propidium Iodide.
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Figure 3: Effects of TET2 silencing on K562 cells’ response to IM. (A) qRT-PCR analysis of miR-29a-3p predicted targets 
performed 24 h after miR-29a-3p transfection. Results were normalized to the NegCTR mimic sample (n = 3). (B) Representation of the 
four miR-29a-3p predicted binding sites in TET2 3′UTR sequence as reported by TargetScanHuman v7.0. The seed region of the miRNA is 
highlighted. (C) Normalized luciferase activity of K562 cells co-nucleofected with miR-29a-3p miRNA mimic and TET2 3′UTR reporter 
vector. Each bar represents the luciferase activity upon miRNA overexpression normalized on the value of the same 3′UTR luciferase vector 
upon Neg-mimic transfection (set to 1). Values are reported as mean ± SEM (n = 3). (D) Western blot analysis of TET2 protein levels in 
whole cell lysates from K562 cells overexpressing miR-29a-3p 48 hours after mimic nucleofection. TET2 protein level in miR-29a-3p 
overexpressing cells was compared with control sample nucleofected with mimic Negative Control (Neg CTR). β-actin was included as 
loading control. (E) TET2 mRNA expression levels 24 hours after the last nucleofection as evaluated by qRT-PCR. Data are reported as RQ 
mean ± S.E.M of 3 independent experiments. Results of Annexin V/PI staining on K562 cells after 24 h (F) and 48 h (G) of IM treatment 
(mean ± SEM; n = 3) *p < 0.05, **p < 0.01. Representative dot plots for flow cytometry detection of Annexin V and PI staining at 24 h and 
48 h after treatment are shown (H), i: NT siRNA, ii: NT siRNA IM 1 μM, iii: TET2 siRNA NT, iv: TET2 siRNA IM 1 μM, v: NT siRNA 
NT, vi: NT siRNA IM 0.4 μM, vii: TET2 siRNA NT, viii: TET2 siRNA IM 0.4 μM. Abbreviations: RQ, Relative Quantity; NT siRNA, Non-
targeting siRNA; siRNA, small interfering RNA; IM, Imatinib Mesylate; NT, Not Treated; 24 h, 24 hours; 36 h, 36 hours; 48 h, 48 hours; 
PI, Propidium Iodide.
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Figure 4: Effects of miR-660-5p overexpression on K562 cells’ response to TKIs. (A) Expression levels of miR-660-5p 
24 hours after the last nucleofection as evaluated by qRT-PCR. Data are reported as RQ mean ± S.E.M of 3 independent experiments. 
The results are expressed as mean values ± SEM (B) Normalized MIF of intracellular p-CrkL levels in K562 cells after miR-660-5p 
overexpression. pCRKL MIF of the Neg CTR mimic untreated control was set to 1 to compare K562 before and after treatment with IM. 
The results are expressed as mean values ± SEM (n = 3) *p < 0.05, **p < 0.01. Results of Annexin V/PI staining on K562 cells after 24 h 
(C) and 48 h (D) of IM treatment (mean ± SEM; n = 3). Representative dot plots for flow cytometry detection of Annexin V and PI staining 
at 24 h and 48 h after treatment are shown (E) i: Neg CTR mimic NT, ii: Neg CTR mimic IM 1 μM, iii: miR-660-5p mimic NT, iv: miR-
660-5p mimic IM 1 μM, v: Neg CTR mimic NT, vi: Neg CTR mimic IM 0,4 μM, vii: miR-660-5p mimic NT, viii: miR-660-5p mimic IM 
0,4 μM). (F) Results of Annexin V/PI staining on K562 cells after 24h of 10nM Ponatinib or 100nM Dasatinib treatment (mean ± SEM; 
n = 3) *p < 0.05, **p < 0.01. Abbreviations: RQ, Relative Quantity; MIF indicates mean fluorescence intensity; IM, imatinib mesylate; NT, 
Not Treated; 24 h, 24 hours; 48 h, 48 hours; PI, Propidium Iodide.
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Figure 5: Effects of EPAS1 silencing on K562 cells’ response to IM. (A) qRT-PCR analysis of miR-660-5p predicted targets 
performed 24 h after miR-660-5p transfection. Results were normalized to the NegCTR mimic sample (n = 3). (B) Representation of the 
two miR-660-5p predicted binding sites in EPAS1 3’UTR sequence as reported by TargetScanHuman v7.0. The seed region of the miRNA is 
highlighted. (C) Normalized luciferase activity of K562 cells co-nucleofected with miR-660-5p miRNA mimic and EPAS1 3′UTR reporter 
vector. Each bar represents the luciferase activity upon miRNA overexpression normalized on the value of the same 3′UTR luciferase vector 
upon Neg-mimic transfection (set to 1). Values are reported as mean ± SEM (n = 3) *p < 0.05, **p < 0.01. (D) Western blot analysis of 
EPAS1 protein levels in whole cell lysates from K562 cells overexpressing miR-660-5p 48 hours after mimic nucleofection. EPAS1 protein 
level in miR-660-5p overexpressing cells was compared with control sample nucleofected with mimic Negative Control (Neg CTR). 
β-actin was included as loading control. (E) EPAS1 mRNA expression levels 24 hours after the last nucleofection as evaluated by qRT-PCR. 
Data are reported as RQ mean ± S.E.M of 3 independent experiments. Results of Annexin V/PI staining on K562 cells transfected with 
EPAS1 siRNA after 24 h (F) and 48 h (G) of IM treatment (mean ± SEM; n = 3). Representative dot plots for flow cytometry detection of 
Annexin V and PI staining at 24 h and 48 h after treatment are shown (H), i: NT siRNA NT, ii: NT siRNA IM 1 μM, iii: EPAS1 siRNA NT, 
vi: EPAS1 siRNA IM 1 μM, v: NT siRNA NT, vi: NT siRNA IM 0.4 μM, vii: EPAS1 siRNA NT, viii: EPAS1 siRNA IM 0.4 μM. *p < 0.05, 
**p < 0.01. Abbreviations: RQ, Relative Quantity; MIF indicates Mean Fluorescence Intensity; IM, Imatinib Mesylate; NT, Not Treated; 
24 h, 24 hours; 48 h, 48 hours; PI, Propidium Iodide.
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Figure 6: Effects of miR-494-3p overexpression on K562 cells’ response to TKIs. (A) Expression levels of miR-494-3p 24 
hours after the last nucleofection as evaluated by qRT-PCR. Data are reported as RQ mean ± S.E.M of 3 independent experiments. (B) 
Normalized MIF of intracellular p-CrkL levels in K562 cells after miR-494-3p overexpression. pCRKL MIF of the Neg CTR mimic 
untreated control was set to 1 to compare K562 before and after treatment with IM. The results are expressed as mean values ± SEM (n = 3). 
Results of Annexin V/PI staining on K562 cells after 24 h (C) and 48 h (D) of IM treatment (mean ± SEM; n = 3) *p < 0.05, **p < 0.01. 
Representative dot plots for flow cytometry detection of Annexin V and PI staining at 24 h and 48 h after treatment are shown (E) i: Neg 
CTR mimic NT, ii: Neg CTR mimic IM 1μM, iii: miR-494-3p mimic NT, iv: miR-494-3p mimic IM 1 μM, v: Neg CTR mimic NT, vi: 
Neg CTR mimic IM 0.4 μM, vi: miR-494-3p mimic NT, viii: miR-494-3p mimic IM 0.4 μM). (F) Results of Annexin V/PI staining on 
K562 cells after 24 h of 10 nM Ponatinib or 100 nM Dasatinib treatment (mean ± SEM; n = 3) *p < 0.05, **p < 0.01. Abbreviations: RQ, 
Relative Quantity; MIF indicates mean fluorescence intensity; IM, imatinib mesylate; NT, Not Treated; 24 h, 24 hours; 48 h, 48 hours; PI, 
Propidium Iodide.
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Figure 7: Effects of MYC silencing on K562 cells’ response to IM. (A) qRT-PCR analysis of miR-494-3p predicted targets 
performed 24h after miR-494-3p transfection. Results were normalized to the NegCTR mimic sample (n = 3). (B) Representation of the 
two miR-494-3p predicted binding sites in MYC 3′UTR sequence as reported by TargetScanHuman v7.0. The seed region of the miRNA is 
highlighted. (C) Normalized luciferase activity of K562 cells co-nucleofected with miR-494-3p miRNA mimic and MYC 3′UTR reporter 
vector. Each bar represents the luciferase activity upon miRNA overexpression normalized on the value of the same 3′UTR luciferase vector 
upon Neg-mimic transfection (set to 1). Values are reported as mean ± SEM (n = 3). (D) Western blot analysis of MYC protein levels in 
whole cell lysates from K562 cells overexpressing miR-494-3p 48 hours after mimic nucleofection. MYC protein level in miR-494-3p 
overexpressing cells was compared with control sample nucleofected with mimic Negative Control (Neg CTR). β-actin was included as 
loading control. (E) MYC mRNA expression levels 24 hours after the last nucleofection as evaluated by qRT-PCR. Data are reported as RQ 
mean ± S.E.M of 3 independent experiments. Results of Annexin V/PI staining on K562 cells after 24 h (F) and 48 h (G) of IM treatment 
(mean ± SEM; n = 3) *p < 0.05, **p < 0.01. Representative dot plots for flow cytometry detection of Annexin V and PI staining at 24 h 
and 48 h after treatment are shown (H) i: NT siRNA NT, ii: NT siRNA IM 1 μM, iii: MYC siRNA NT, iv: MYC siRNA IM 1 μM, v: NT 
siRNA NT, vi: NT siRNA IM 0.4 μM, vii: MYC siRNA NT, viii: MYC siRNA IM 0.4 μM). Abbreviations: RQ, Relative Quantity; NT 
siRNA, Non-targeting siRNA; siRNA, small interfering RNA; IM, Imatinib Mesylate; NT, Not Treated; 24 h, 24 hours; 48 h, 48 hours; PI, 
Propidium Iodide.
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that in vivo TKI therapy is able to clear most of Ph+ cells 
from the stem cell compartment [13]. These differences 
might be due to the different time points applied for LSCs 
analysis, usually at diagnosis for in vitro studies, at later 
time points in the work by Mustjoki et al. or to technical 
limitations that might have prevented the identification 
of few residual LSCs. Typically, CML stem cells have 
been defined as lineage-negative CD34-positive CD38-
negative (Lin-CD34+CD38−) cells. However, our group 
recently identified a new subset of LSCs negative for 
CD34 expression, therefore identified as Lin-CD34-CD38- 
cells [6]. Our data demonstrate that approximately one-
third of Lin-CD34-CD38- cells are leukemic and capable 
of engraftment in immunodeficient mice. Moreover, these 
cells showed intrinsic resistance to IM both in vitro and in 
vivo. Therefore, Lin-CD34-CD38- CML cells can be seen 
as a stem cell subset insensitive to targeted therapy that 
may contribute to disease persistence.
In the last years, miRNAs expression has been 
reported to be deregulated in hematological malignancies 
[10], where it is responsible for disease development or 
maintenance. 
Based on these premises, in order to gain further 
understanding on the molecular features of the CML 
stem cell compartment, we analyzed the miEP of both 
Lin-CD34-CD38- and Lin-CD34+CD38− LSCs, and 
miRNAs deregulated in both cell fractions were selected. 
Our analysis identified 33 differentially expressed 
miRNAs in the comparison LSCs vs HSCs (Figure 1B). 
As Corbin et al. demonstrated that LSCs escape from 
IM treatment independently from BCR-ABL kinase 
activity, we sought to identify those miRNAs that were 
deregulated in CML LSCs with a mechanism that is 
independent from BCR-ABL. To this aim, BCR-ABL-
positive K562 cells were treated with increasing doses 
of IM and miRNAs, whose expression did not change 
after IM treatment, were selected and classified as BCR-
ABL-independent miRNAs. This analysis unraveled 
8 miRNAs, whose expression is deregulated in CML 
LSCs independently from BCR-ABL (Figure 1F). Next, 
in order to assess whether the deregulated expression of 
such miRNAs was able to affect TKIs-sensitivity, miRNA 
overexpression experiments were performed. As initial 
analysis, the function of selected miRNAs was studied 
in K562 cells, then, in order to validate our results, 
miRNA overexpression experiments were performed in 
Hematopoietic Stem/Progenitor Cells (HSPCs) isolated 
from CML patients collected in chronic phase before 
therapy. All eight BCR-ABL-independent miRNAs, except 
miR-486 whose role in CML has been recently described 
by Dr. Bhatia’s group [14], were studied. Our results 
demonstrated that the overexpression of miR-204-5p, 
miR-19b-2-5p, and miR-365a-3p do not affect IM 
response in K562 cells (data not shown). On the other 
hand, miR-29a-3p, miR-660-5p and miR-494-3p showed 
a strong influence on TKIs sensitivity when overexpressed 
in BCR-ABL-positive cells. In particular, miR-29a-3p 
overexpression was able to protect cells from TKIs-induced 
apoptosis (Figure 2C–2F). Of note, IM-induced BCR-
ABL kinase inhibition was not affected by miR-29a-3p 
expression level (Figure 2B), therefore demonstrating 
that miR-29a-3p up-regulation is able to confer IM-
resistance with a BCR-ABL-independent mechanism. 
By means of 3′UTR luciferase reporter assay, we were 
able to demonstrate for the first time in the hematopoietic 
context the direct interaction between miR-29a-3p and 
TET2 (Figure 3C). Moreover, TET2 silencing mimicked 
the effects induced by miR-29a-3p overexpression, 
suggesting that miR-29a-3p protects cells from IM-
induced apoptosis through TET2 targeting. Han YC et al. 
provided evidence that miR-29a-3p may serve as oncogene 
during Acute Myeloid Leukemia (AML) development: 
ectopic expression of miR-29a induce the acquisition 
of self-renewal capacity by myeloid progenitors, 
biased myeloid differentiation, and the development 
of a myeloproliferative disorder [15]. Somatic loss of 
function mutations in TET2 are frequently observed in 
myelodysplastic syndromes (MDS), myeloproliferative 
neoplasms (MPN), and AML [16, 17]. Recently, decreased 
TET2 expression associated with t(4;6;11) rearrangement 
has been demonstrated to be involved in CML progression. 
Of note, the appearance of the TET2 deletion was not 
associated with an increase of the BCR-ABL transcript 
level, suggesting a BCR-ABL-independent role for this 
gene in CML progression [18]. Our data strongly suggest 
that the up-regulation of miR-29a-3p observed in CML 
LSCs is responsible for TET2 downregulation, which 
in turn is able to confer IM-resistance to CML LSCs. 
These findings imply that TET2 could be involved in the 
pathogenesis of myeloid malignancies through deregulated 
gene expression in addition to inactivating mutations and 
provide a rationale for targeted therapies that impact TET2 
aberrant regulation.
Among miRNAs up-regulated in CML LSCs with 
a BCR-ABL-independent mechanism, our analysis 
pointed out miR-660-5p. miR-660-5p has been previously 
reported in the context of hematopoiesis as involved in 
polyploidization and megakaryocytes differentiation [19]. 
To our knowledge, this is the first report describing a role 
for miR-660-5p in myeloid malignancies. miR-660-5p 
overexpression was able to protect cells from TKIs-induced 
apoptosis (Figure 4C–4F). IM-induced BCR-ABL kinase 
inhibition was not affected by miR-660-5p expression 
level (Figure 4B), therefore demonstrating that miR-660-
5p up-regulation is able to confer IM-resistance to K562 
cells with a BCR-ABL-independent mechanism. Between 
miR-660-5p predicted targets, EPAS1 showed significant 
downregulation upon miR-660-5p overexpression 
both at the mRNA and protein level (Figure 5A and 5D 
respectively). EPAS1 silencing was able to protect cells 
from IM-induced apoptosis thus phenocopying the 
effects induced by miR-660-5p overexpression (Figure 
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Figure 8: miR-29a-3p, miR-660-5p and miR494-3p overexpression in HSPCs isolated from CML patients. (A) Expression 
levels of miR-29a-3p, miR-494-3p and miR-660-5p 24 hours after the last nucleofection as evaluated by qRT-PCR. Data are reported as RQ 
mean ± S.E.M of 3 independent experiments. Results of Annexin V/PI staining on Lin-CD34-CD38− (B) and Lin-CD34+CD38− (C) cells 
isolated from CML patients after 48 h of 5 μM IM, or 200 nM Dasatinib or 20 nM Ponatinib treatment (mean ± SEM; n = 3) *p < 0.05, 
**p < 0.01. Abbreviations: RQ, Relative Quantity; IM, imatinib mesylate; Das, Dasatinib; Pon, Ponatinib; NT, Not Treated; 48 h, 48 hours; 
PI, Propidium Iodide.
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5F–5H). EPAS1, also known as hypoxia-inducible factor 
2 alpha (HIF2A), is a transcription factor critical for the 
adaptive response to hypoxia. HIF2A expression has been 
associated with aggressive disease phenotype, metastasis 
and resistance to therapy in several solid tumors, such as 
neuroblastoma [20], non-small cell lung cancer [21], and 
breast cancer [22]. On the other hand, recent evidence 
showed that in HIF-2a inhibits high-grade soft tissue 
sarcomas cell growth in vivo [23], suggesting a cell 
context-dependent role for EPAS1 in tumor development. 
Our data strengthen this hypothesis, in fact, in the CML 
context, EPAS1 down-regulation is involved in the escape 
from IM treatment of BCR-ABL-positve cells.
On the other hand, between miRNAs down-regulated 
in CML LSCs independently from BCR-ABL activity, our 
miEP data highlighted miR-494-3p (Figure 1E, 1F). miR-
494 has been reported as an oncogenic miRNA in a variety 
of cancers including colorectal cancer  [24], breast cancer 
[25], ovarian cancer [26], and prostate cancer [27]. However, 
in several solid tumors, i.e. oral and gastric cancer, miR-
494-3p acts as an anti-oncogene by targeting HOXA10 and 
c-MYC respectively [28, 29]. Our data demonstrated that 
miR-494-3p overexpression is able to sensitize K562 cells 
to TKIs-induced apoptosis without affecting BCR-ABL 
kinase acitvity (Figure 6C–6F). Thus suggesting that miR-
494-3p acts as tumor suppressor miRNA in CML, where 
its downregulation is necessary for the intrinsic resistance 
to TKIs that characterizes LSCs. In order to identify the 
molecular mechanisms governing miR-494-3p-induced IM 
sensitization, 3’UTR luciferase assay was performed and 
c-MYC was identified as  miR-494-3p target (Figure 7C). 
At the time this manuscript was in preparation, Tian C. et 
al. [30] reported c-MYC downregulation upon miR-494-3p 
overexpression in AML cell lines. To our knowledge, these 
are the first two reports demonstrating c-MYC targeting by 
miR-494-3p in hematological malignancies. Noteworthy, 
c-MYC silencing was able to sensitize cells to IM-induced 
apoptosis (Figure 7F–7H), thus mimicking the effects induced 
by miR-494-3p overexpression. Recently an interesting dual 
role for c-MYC in CML has been reported: Reavie L. et al. 
showed that both depletion and overexpression of c-MYC can 
severely impact CML progression, suggesting that a specific 
level of c-Myc protein is essential for CML induction and 
progression [31]. In this view, our results suggest that c-MYC 
overexpression induced by miR-494-3p downregulation in 
LSCs is strongly connected to BCR-ABL-independent 
TKI-resistance. This hypothesis opens the way for novel 
therapeutic strategies combining TKI and c-Myc inhibitors 
to effectively target CML LSCs.
Worth of note, our data also demonstrated that 
ectopic expression of miR-29a-3p, miR-494-3p and miR-
660-5p was able to affect the response to first, second 
and third generation TKIs of HSPCs isolated from CML 
patients (Figure 8B, 8C), therefore suggesting that their 
deregulated expression observed in CML LSCs might be 
responsible for the escape from TKIs treatment in vivo. 
In summary, our analysis uncovered several 
miRNAs aberrantly expressed in CML LSCs. In particular, 
we identified those miRNAs that are deregulated in 
LSCs independently from BCR-ABL kinase activity and 
therefore are likely to be involved in the BCR-ABL-
independent resistance to TKI that characterizes CML 
LSCs. This work unraveled three mRNA/miRNA networks 
(miR-29a-3p/TET2, miR-660-5p/EPAS1 and miR-494-3p/
c-MYC) capable of affecting TKI-sensitivity in CML cells, 
thus leading to the design of novel targeted therapies aimed 
at eliminating TKI-resistant LSCs.
MATERIALS AND METHODS
Patients and samples
Leukemic cells were obtained from peripheral blood 
(PB) of 10 chronic phase Ph+ CML patients at diagnosis, 5 
were analysed for miRNA expression profiling, 5 were used for 
miRNA overexpression experiments (Supplementary Table 1). 
Normal samples were leukapheresis products from 4 healthy 
donors receiving recombinant human granulocyte colony-
stimulating factor (G-CSF; Lenograstim; Sanofi-Aventis). 
All subjects provided informed written consent, and the study 
was performed under the local Institutional Review Board’s 
approved protocol (GIMEMA CML0811, clinicaltrials.gov 
identifier: 01535391; CE approval, Bologna, 13/09/2011, n. 
70/2011/U). The study was conducted in accordance with 
the Declaration of Helsinki. Hematopoietic stem/progenitor 
cell purification and phenotypic analyses were performed as 
previously described [32, 33]. Aliquots of sorted Lin−CD34−
CD38- and Lin−CD34+CD38- were reanalyzed by FACScan 
(Becton Dickinson) to assess their purities, which were 98.8% 
(± 0.5%) and 99.1% (± 0.8%), respectively (Supplementary 
Figure 1). As previously reported [6], FISH analysis and RQ-
PCR for BCR-ABL transcript demonstrated that Ph+ cells were 
70.5% (± 5%), and 32% (± 2%) of total Lin-CD34+CD38− 
and Lin-CD34-CD38- CML cells at diagnosis, respectively.
RNA extraction
Total cellular RNA was harvested from 1 × 105 cells 
from each sample using the miRNeasy Micro RNA isolation 
kit (QIAGEN), according to the manufacturer’s instructions. 
RNA samples concentration and purity (assessed as 260/280 
nm and 260/230 nm ratios) were evaluated by NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies; 
Wilmington, DE), while RNA integrity was assessed by 
using the Agilent 2100 Bioanalyzer (Agilent Technologies; 
Waldbrunn, Germany).
miRNA expression profiling
miEP was performed by using the miRCURY LNATM 
Universal RT microRNA PCR system, Ready-to-use 
Human miRNome Panels I and II (Exiqon, Copenhagen, 
Oncotarget49466www.impactjournals.com/oncotarget
Denmark). RT-qPCR data were analysed using the 
Exiqon GenEx software for the inter-plate calibration, 
the definition of a Ct=40 as detection cutoff, the labeling 
of not-amplified wells as missing data and the setting 
of a cutoff for miRNAs with a low call-rate (i.e. assays 
with a detection rate < 33,3%, i.e. assays not detected 
in 12 out of 18 samples, were excluded from analysis). 
For RT-qPCR data normalization, the comparative cycle 
threshold (CT) method was used by setting miR-23a-3p, 
miR-24-3p and miR-324-3p as reference miRNAs, as 
the best normalizers identified among the candidates by 
the NormFinder algorithm. The Relative Quantity (RQ) 
value was expressed as 2−ΔΔCT. Statistical analyses on ΔCT 
values between CML Lin-CD34-CD38- and Normal donor 
Lin-CD34-CD38− (set as calibrator) and between CML 
Lin-CD34+CD38− and Normal donor Lin-CD34+CD38- 
(set as calibrator) were performed by a two-tail unpaired 
t-Student test using the GenEx software. Differentially 
expressed miRNAs (DEMs) in the Lin-CD34-CD38- cell 
population were selected as the miRNAs with a Relative 
Quantity (RQ) ≥ 2 or ≤ 0.5 (p < 0.05) in the comparison 
between CML Lin-CD34-CD38− and Normal donor Lin-
CD34-CD38- samples. DEMs in the Lin-CD34+CD38− 
cell population were selected as the miRNAs with a 
Relative Quantity (RQ) ≥ 2 or ≤ 0.5 (p < 0.05) in the 
comparison between CML Lin-CD34+CD38− and Normal 
donor Lin-CD34+CD38− samples. miEP data have been 
deposited in the GEO public database [34] (http://www.
ncbi.nlm.nih.gov/geo; series GSE90773).
Quantitative reverse transcription polymerase 
chain reaction (qRT-PCR)
Total RNA (100 ng) was reverse-transcribed to 
cDNA using a High Capacity cDNA Archive Kit (Life 
technologies; Carlsbad, CA, USA). TaqMan PCR was 
carried out using the TaqMan Fast Advanced PCR master 
mix and TaqMan gene expression assays (all reagents 
from Life Technologies), by means of a 7900HT Fast 
Real-Time PCR System (Applied Biosystems). Assays 
were performed in triplicate. Gene expression profiling 
was achieved using the comparative cycle threshold (CT) 
method of relative quantitation using Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as housekeeping 
genes. To normalize data, ΔΔCT was calculated for each 
sample using the mean of its ΔCT values subtracted from 
the mean ΔCT value measured in the control sample, 
set as a calibrator; relative quantitation (RQ) value was 
expressed as 2−ΔΔCT.
Individual miRNA detection by RT-qPCR was 
performed using the TaqMan MicroRNA assays (Life 
technologies). Individual reverse transcription reactions 
(5 ng of total RNA each target) were performed using 
the Taqman microRNA Reverse Transcription Kit and 
the miRNA-specific looped-primers. TaqMan PCR 
was performed in triplicate by using the 7900HT Fast 
Real-Time PCR System (Applied Biosystems). miRNA 
expression RQ data were calculated as reported above, 
using U6 snRNA as housekeeping control.
Electroporation of K562 cells
K562 cells were electroporated by means of the 
Amaxa 4D-Nucleofector™ System, according to the 
manufacturer’s instructions. Briefly, K562 cells were 
subcultured at a density of 3 × 105 cells/mL 2 days before 
nucleofection in Iscove’s-modified Dulbecco medium 
(IMDM; Euroclone) supplemented with 10% FBS (Sigma-
Aldrich). Each sample was electroporated two times once 
every 24 hours (h) with 3 µg of mirVana™ miR-29a-3p 
mimic or mirVana™ miR-494-3p mimic or mirVana™ 
miR-660-5p mimic or mirVana™ miRNA mimic Negative 
Control #1 (Neg CTR mimic) (Supplementary Table 4) 
(all from Life Technologies). For each electroporation, 106 
cells were resuspended in 100 μL of SF Cell line Solution 
(Lonza) and pulsed with the program FF120. For gene 
silencing experiments, each sample was electroporated 
two times once every 24 hours (h) with 5 µg of Silencer 
Select small interfering RNA (siRNA) targeting human 
EPAS1, TET2 or MYC. To exclude non-specific effects 
caused by interfering RNA (RNAi) nucleofection, a 
sample transfected with a non-targeting siRNA (NT 
siRNA; Silencer Select Negative Control #2 siRNA; Life 
Technologies) (Supplementary Table 4) was included. After 
each transfection, K562 cells were transferred into pre-
warmed fresh medium in 12-well plates and maintained 
in the same culture conditions as described above. 24 h 
after last nucleofection, cells were treated with IM 1 μM 
or 0.4 μM (Sigma-Aldrich), or  Dasatinb 100 nM or 25 nM 
(Bristol-Myers Squibb) or Ponatinib 10 nM or 2,5 nM (Ariad 
Pharmaceuticals) for additional 24 and 48 h respectively.
For 3′UTR luciferase reporter assays, cells were 
transiently co-nucleofected with either a miRNA mimic 
or miRNA mimic negative control (Neg CTR mimic) 
at a concentration of 3.6 μM and with either 3′UTR-
less luciferase or a full-length 3′UTR construct at a 
concentration of 200 ng/sample. For each electroporation, 
106 cells were resuspended in 100 μL of SF Cell line 
Solution (Lonza) and pulsed with the program FF120.
CrkL phosphorylation assay
The CrkL Tyr207-phosphorylation assay was 
performed in untreated and IM-treated K562 cells after 
either 24h or 48h of IM treatment. For each datapoint, 
105 cells per sample were labeled for PCrkL as already 
described [35]. Cells were analyzed by BD FACSCanto 
II (BD Biosciences; San Jose, CA USA). At least 10000 
events were counted for each sample to ensure statistical 
relevance. The resulting flow cytometry data were 
normalized according to the mean fluorescent intensity 
(MIF) so that the untreated control K562 cell population 
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for each sample had pCrkl MIF = 1. Then, the results for 
each sample were calculated as a fraction of this. 
Annexin V/PI staining
Apoptosis was evaluated by Annexin V assay 
(Annexin V-FITC Kit, Trevigen Inc.) as previously 
described [36]. Briefly, 5 × 105 cells were washed with cold 
PBS and incubated in 100 μL Annexin V Incubation Reagent 
for 15 min at room temperature in the dark. After staining, 
cells were analyzed by using a BD FACSCanto II (BD 
Biosciences; San Jose, CA USA). At least 100,000 events 
were counted for each sample to ensure statistical relevance. 
Apoptotic cells are Annexin V bright and Propidium Iodide 
(PI) low, late apoptotic cells or necrotic cells are Annexin V 
and PI bright [37].
3′UTR luciferase reporter assays
Empty luciferase reporter constructs (pEZX-MT01) 
or plasmids containing wild-type full-length 3′UTR from 
human TET2 (RefSeq NM_001127208.2), human c-MYC 
(RefSeq NM_002467.4) and human EPAS1 (RefSeq 
NM_001430.4) transcripts were all purchased from 
Labomics (Genecopoeia; MD, USA). Luciferase assay and 
its following normalization were performed as previously 
reported [12].
Western blot
Protein levels were assessed by means of Western 
Blot Analysis in K562 cells (ATCC) overexpressing 
either miR-29a-3p, miR-660-5p or miR-494-3p. Briefly, 
cells were harvested 48 hours after the last nucleofection, 
washed twice with cold phosphate-buffered saline 
(PBS) and lysed in 50 mM Tris (tris(hydroxymethyl) 
aminomethane)-Cl (pH 7.4), 150 mM NaCl, 1% 
Nonidet P-40, 10 mM KCl, 1 mM EDTA, 20 mM NaF, 
0.25% Na doexycholate, 5 mM dithiothreitol (DTT). 
Protease inhibitors (Roche, Indianapolis, IN, USA 
Complete, catalog #1697498) and phosphatase inhibitors 
(ThermoFisher Scientific) were added to the lysis buffer. 
Total cellular lysates (50 µg for each sample) were 
loaded and separated on 10% SDS-polyacrylamide gel 
and then transferred on a nitrocellulose membrane. To 
visualize loading and transfer, Ponceau staining has 
been performed. Membranes were then pre-blocked in a 
blocking solution of tris-buffered saline (TBS) containing 
5% non-fat dry milk (NFDM) and then incubated with 
the following primary antibodies: mouse monoclonal 
anti-TET2 antibody (SantaCruz Biotechnology, Inc, 
Dallas, Texas, USA; catalog# sc-398535, 1:100 dilution 
at 4°C overnight), rabbit monoclonal anti-MYC 
antibody (Abcam; catalog #ab32072; 1:200 dilution at 
4°C overnight), rabbit polyclonal anti-EPAS1 antibody 
(Novus Biological, catalog #NB100-122; 1:500 dilution 
at 4°C overnight), and with rabbit polyclonal anti-β-actin 
primary antibody (Thermo Fisher Scientific Inc, catalog 
#PA1-16889; 1:2000 dilution for 1 hour at RT). The blots 
were washed for three times with TBS and then incubated 
with 1:5000 dilution of horseradish peroxidase (HRP) 
conjugated goat anti-mouse (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA catalog #sc-2005) and/or 1:1000 
dilution of HRP-conjugated goat anti-rabbit secondary 
antibody (Thermo Fisher Scientific Inc., catalog #32460) 
for 1 h at RT secondary antibodies. After three successive 
washes with TBS, BM chemiluminescence Blotting 
Substrate (POD) (Roche) was used for protein detection.
CML hematopoietic stem/progenitor cells’ 
isolation and culture
Lineage negative cells from 5 CML patients 
(Supplementary Table 1) were isolated by means of a 
custom-made Easy Sep Negative Selection Cocktail 
(StemCell Technologies, Canada). Lin- cells were seeded 
at 5 × 105 cells/mL in serum-free medium SYN-H 
(ABCell-Bio, Paris, France), supplemented with stem cell 
factor (SCF; 50 ng/mL), Fms-like tyrosine kinase 3 ligand 
(Flt3L; 50 ng/mL), thrombopoietin (TPO; 20 ng/mL), 
interleukin-6 (IL-6; 10 ng/mL), and interleukin-3 (IL-3; 
10 ng/mL; all from Miltenyi). Lin- cells were transfected 
using the 4D-Nucleofector™ System (Lonza) as previously 
reported [36]. 24 h after last nucleofection cells were 
treated with IM 10 μM or 5 μM (Sigma-Aldrich) for 24 h 
and 48 h respectively, or 200 nM Dasatinib (Bristol-Myers 
Squibb) or 20 nM Ponatinib (Ariad Pharmaceuticals) for 
additional 48 h.
Statistical analysis
The statistics used for data analysis in overexpression/
silencing experiments and 3′UTR luciferase reporter assays 
were based on one-way ANOVA and 2-tailed Student t-tests 
for average comparisons in paired samples (equal variance). 
Data were analyzed with Microsoft Excel (Microsoft 
Office, 2011 release) and StatPlus:mac LE (AnalystSoft) 
and are reported as mean ± standard error of the mean 
(SEM). A p-value < 0.05 was considered significant. 
Supplementary Table 7.
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